Leveraging advanced computational biology and genetic engineering, Stellanova Therapeutics focuses on developing innovative cancer treatments by targeting cancer-associated fibroblasts (CAFs) and their interactions within the tumor microenvironment. The company's research, based on Dr. Rosa Hwang's work at MD Anderson Cancer Center, has shown promising results in combating cancer and increasing vulnerability to traditional therapies like chemotherapy and immunotherapy. With a mission to establish a groundbreaking approach to cancer treatment, Stellanova Therapeutics aims to address the challenges posed by resistant cancers through its drug pipeline targeting CAFs, which has demonstrated unprecedented anti-tumor activity in multiple resistant cancer models.